Dianthus Therapeutics Banner

Analyst Coverage

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Press Release
Firm Analyst
Cantor Fitzgerald
 Pete Stavropoulos, Ph.D.
Clear Street
 Bill Maughan, Ph.D.
Evercore ISI
 Gavin Clark-Gartner
Guggenheim
 Yatin Suneja
H.C. Wainwright & Co.
 Swayampakula Ramakanth, Ph.D.
Jefferies
 Maury Raycroft, Ph.D.
LifeSci Capital
 Rami Katkhuda
Oppenheimer & Co.
 Trevor Allred
Raymond James
 Ryan Deschner
Robert W. Baird & Co.
 Colleen Kusy, CFA
Stifel
 Alex Thompson
TD Cowen
 Yaron Werber, M.D.
Truist
 Danielle Brill
Wedbush
 Laura Chico, Ph.D.
William Blair
 Myles Minter, Ph.D.

Dianthus Therapeutics is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Dianthus Therapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Dianthus Therapeutics or its management. Dianthus Therapeutics does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.